These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 27993598)

  • 1. Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation.
    Rokad D; Ghaisas S; Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Brain Res Bull; 2017 Jul; 133():60-70. PubMed ID: 27993598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seeded propagation of α-synuclein aggregation in mouse brain using protein misfolding cyclic amplification.
    Nicot S; Verchère J; Bélondrade M; Mayran C; Bétemps D; Bougard D; Baron T
    FASEB J; 2019 Nov; 33(11):12073-12086. PubMed ID: 31370680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ellagic Acid Prevents α-Synuclein Aggregation and Protects SH-SY5Y Cells from Aggregated α-Synuclein-Induced Toxicity via Suppression of Apoptosis and Activation of Autophagy.
    Ardah MT; Eid N; Kitada T; Haque ME
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
    Melki R
    J Parkinsons Dis; 2015; 5(2):217-27. PubMed ID: 25757830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-synuclein aggregation and its modulation.
    Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
    Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.
    Luna E; Luk KC
    FEBS Lett; 2015 Dec; 589(24 Pt A):3749-59. PubMed ID: 26505673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
    Oh Y
    BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses.
    Jan A; Gonçalves NP; Vaegter CB; Jensen PH; Ferreira N
    Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
    Peng C; Gathagan RJ; Lee VM
    Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein: normal function and role in neurodegenerative diseases.
    Norris EH; Giasson BI; Lee VM
    Curr Top Dev Biol; 2004; 60():17-54. PubMed ID: 15094295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the Cover: Arsenic Induces Accumulation of α-Synuclein: Implications for Synucleinopathies and Neurodegeneration.
    Cholanians AB; Phan AV; Ditzel EJ; Camenisch TD; Lau SS; Monks TJ
    Toxicol Sci; 2016 Oct; 153(2):271-81. PubMed ID: 27413109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein.
    Xu MM; Ryan P; Rudrawar S; Quinn RJ; Zhang HY; Mellick GD
    Acta Pharmacol Sin; 2020 Apr; 41(4):483-498. PubMed ID: 31586134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease.
    Aureli C; Cassano T; Masci A; Francioso A; Martire S; Cocciolo A; Chichiarelli S; Romano A; Gaetani S; Mancini P; Fontana M; d'Erme M; Mosca L
    J Neurosci Res; 2014 Mar; 92(3):347-58. PubMed ID: 24273027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.
    Vargas JY; Grudina C; Zurzolo C
    Ageing Res Rev; 2019 Mar; 50():89-101. PubMed ID: 30690184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.